Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica.

Literature DB >> 20439532

Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica.

Keisuke Hagihara, Ichiro Kawase, Toshio Tanaka, Tadamitsu Kishimoto.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2010 PMID： 20439532 DOI： 10.3899/jrheum.091185

Source DB: PubMed Journal: J Rheumatol ISSN： 0315-162X Impact factor: 4.666

Keyword Cloud
Cited

× No keyword cloud information.

19 in total

1. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.

Authors: X Palard-Novello; S Querellou; M Gouillou; A Saraux; T Marhadour; F Garrigues; R Abgral; P Y Salaün; V Devauchelle-Pensec
Journal: Eur J Nucl Med Mol Imaging Date: 2016-01-11 Impact factor: 9.236

Review 2. IL-6 biology: implications for clinical targeting in rheumatic disease.

Authors: Leonard H Calabrese; Stefan Rose-John
Journal: Nat Rev Rheumatol Date: 2014-08-19 Impact factor: 20.543

3. Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition.

Authors: Dario Camellino; Stefano Soldano; Maurizio Cutolo; Marco A Cimmino
Journal: Rheumatol Int Date: 2018-06-26 Impact factor: 2.631

Review 4. Tocilizumab (Actemra).

Authors: Martin Sheppard; Faidra Laskou; Philip P Stapleton; Shahryar Hadavi; Bhaskar Dasgupta
Journal: Hum Vaccin Immunother Date: 2017-09-02 Impact factor: 3.452

Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica.

1. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.

Review 2. IL-6 biology: implications for clinical targeting in rheumatic disease.

3. Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition.

Review 4. Tocilizumab (Actemra).

Review 5. Clinical features of polymyalgia rheumatica and giant cell arteritis.

6. Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica.

Review 7. Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Review 8. Genetics of asthma susceptibility and severity.

Review 9. [Interleukin-6 inhibition as a potential therapeutic target in rheumatic diseases].

10. Clinical use of biologics in vasculitis syndromes.